Boehringer Ingelheim launches RE-VECTO Global Program to capture data on Praxbind usage in clinical practice

RE-VECTO will provide insights into the diverse types of situations in which reversal of an anticoagulant is performed in clinical practice.

"Praxbind was made available immediately following FDA approval in October 2015, and is now stocked in more than 2,760 hospital pharmacies in all 50 states," said Sabine Luik, senior vice president, Medicine & Regulatory Affairs, Boehringer Ingelheim Pharmaceuticals, Inc. "By their nature, every emergency situation is unique. We believe that RE-VECTO will provide important additional insights into the different situations Praxbind is used in. This may ultimately help improve care for Pradaxa patients in the rare event that reversal is needed."

Data for RE-VECTO will be captured through hospital pharmacies where Praxbind is dispensed and will include information about the types of patients and situations in which Praxbind was utilized. The data gathered from RE-VECTO will help shape future information and education on Praxbind to healthcare providers and patients.